* Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets * Collaboration to create, develop, ...
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that ...
IGM Biosciences, Inc. is a leader in IgM antibody development. It stuck a major deal with Sanofi last year. Decent data, proof of concept, and good cash runway make IGM Biosciences, Inc. attractive.
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. IGM Biosciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate ...
Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the shares. The firm is citing the company’s announcement that ...
Antibodies are behind some of the world’s best-selling drugs, and it seems that progress in the field continues to generate big price tags and headlines. Using data provided by DealForma for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback